A phenotypic signature-based strategy that identifies tumor-specific TCR in fresh human colorectal cancers

Despite advances in cancer immunotherapy, solid tumors remain challenging due to antigenic heterogeneity and immunosuppressive microenvironments. T-cell receptor-engineered T cells (TCR-T) hold promises by targeting intracellular antigens, yet identifying tumor-specific TCRs is hindered by the rarity of tumor-reactive T cells. Here, we developed a phenotypic signature-based strategy to efficiently isolate tumor-specific TCRs from colorectal cancer (CRC) tumor-infiltrating lymphocytes (TILs). We leveraged the co-expression of surface markers CD39, CD103, and PD-1 to enrich CXCL13 + CD8 + T cells, a subset linked to tumor reactivity and improved patient survival. Single-cell RNA sequencing and flow cytometry of a small cohort CRC patients revealed that triple-positive (CD39 + CD103 + PD-1 + ) CD8 + TILs exhibited the highest CXCL13 enrichment, providing a basis for subsequent TCR clonotype identification. High-throughput TCR sequencing of the enriched cells identified dominant clonotypes, which were validated using autologous tumor organoids. A top candidate TCR (TCR-1A7) demonstrated robust tumor-specific cytotoxicity, as evidenced by upregulated activation markers (CD69, CD137), cytokine secretion (IFN-γ, granzyme B), and tumor organoid apoptosis, while sparing normal tissues. MHC blockade confirmed antigen-specific recognition. Combining phenotypic profiling, TCR screening, and organoid-based validation, this integrative approach proposes a potential framework for developing precision TCR-T therapies against solid tumors, addressing critical bottlenecks in efficacy and safety.

Authors

Institutions

Publication Details

Journal
Cancer Immunology Immunotherapy
Published
2026-11-13
DOI
https://doi.org/10.1007/s00262-026-04634-2
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A phenotypic signature-based strategy that identifies tumor-specific TCR in fresh human colorectal cancers

Yixian Li, Qianjing Zhang, Xuan Che, Yuan Sun et al.
5 links
Cancer Immunology Immunotherapy
CAR-T cell therapy research
article

A phenotypic signature-based strategy that identifies tumor-specific TCR in fresh human colorectal cancers

Yixian Li, Qianjing Zhang, Xuan Che, Yuan Sun, Pengchong Zhang, Lisha Ma, Xiya Wang, Yun Bai, Zhilang Li, Xiangwen Ji
article en

Abstract

Despite advances in cancer immunotherapy, solid tumors remain challenging due to antigenic heterogeneity and immunosuppressive microenvironments. T-cell receptor-engineered T cells (TCR-T) hold promises by targeting intracellular antigens, yet identifying tumor-specific TCRs is hindered by the rarity of tumor-reactive T cells. Here, we developed a phenotypic signature-based strategy to efficiently isolate tumor-specific TCRs from colorectal cancer (CRC) tumor-infiltrating lymphocytes (TILs). We leveraged the co-expression of surface markers CD39, CD103, and PD-1 to enrich CXCL13 + CD8 + T cells, a subset linked to tumor reactivity and improved patient survival. Single-cell RNA sequencing and flow cytometry of a small cohort CRC patients revealed that triple-positive (CD39 + CD103 + PD-1 + ) CD8 + TILs exhibited the highest CXCL13 enrichment, providing a basis for subsequent TCR clonotype identification. High-throughput TCR sequencing of the enriched cells identified dominant clonotypes, which were validated using autologous tumor organoids. A top candidate TCR (TCR-1A7) demonstrated robust tumor-specific cytotoxicity, as evidenced by upregulated activation markers (CD69, CD137), cytokine secretion (IFN-γ, granzyme B), and tumor organoid apoptosis, while sparing normal tissues. MHC blockade confirmed antigen-specific recognition. Combining phenotypic profiling, TCR screening, and organoid-based validation, this integrative approach proposes a potential framework for developing precision TCR-T therapies against solid tumors, addressing critical bottlenecks in efficacy and safety.

Cancer Immunology Immunotherapy
Peking University (CN), Chinese PLA General Hospital (CN), Peking University Third Hospital (CN)
Good health and well-being
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon